25 The SAFE Drugs Act 2025: Compliance as a Barrier to Entry If you thought the current rules were tough, wait until you see the Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025
The most common injuries associated with these medications include: Gastrointestinal injuries: Many patients report severe gastroparesis (delayed stomach emptying), persistent vomiting, chronic nausea, abdominal pain, intestinal obstruction, and bowel injuries
Dear Marci, My doctor and I have been discussing some of the new GLP-1 weight loss medications
How much weight can you expect to lose with Ozempic as a GLP-1 medication
It plays a major role in: Slowing how quickly food leaves your stomach Helping you feel full longer Reducing blood sugar spikes Supporting fat loss when managed effectively This hormone is one reason high-protein, whole food diets can feel so satisfying they naturally help your body release GLP-1
Plaintiff OFA Appeals | Foley & Lardner, accessed February 2, 2026, Major Update on GLP-1 Litigation involving Compounding Pharmacies, accessed February 2, 2026, Semaglutide & Tirzepatide Patent Considerations DiversifyRx, accessed February 2, 2026, GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List | Foley & Lardner, accessed February 2, 2026, Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding | Pharmacy Times, accessed February 2, 2026, Despite Obesity Drug Pricing Deal, GLP-1 Compounders Continue To Operate in the Shadows BioSpace, accessed February 2, 2026, FDA Compliance Alert for Weight Management Providers: Compounded GLP-1s with Additives Montgomery Purdue, accessed February 2, 2026, GLP-1 Drugs: Ohio Board of Pharmacy Issues FAQs for Compounders | Foley & Lardner, accessed February 2, 2026, The Heavy Price of GLP-1 Drugs I-MAK, accessed February 2, 2026, Top 12 Drug Patents Expiring as early as February 2025 GreyB, accessed February 2, 2026, FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, accessed February 2, 2026, GLP-1 Litigation and the Road Ahead for Independent Pharmacies | Drug Topics, accessed February 2, 2026, FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers, accessed February 2, 2026, Beyond the Headlines: FDA Warning Letters to GLP-1 Compounders Spencer Fane, accessed February 2, 2026, Compounding Pharmacy Sues Eli Lilly, Novo Nordisk Over Alleged , accessed February 2, 2026, Compounder sues Lilly and Novo for suppressing GLP-1RA competition, accessed February 2, 2026, Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access, accessed February 2, 2026, The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026, accessed February 2, 2026, Yakym, Carson Introduce Bill to Protect Patients from Unsafe , accessed February 2, 2026, Client Alert: Recent State and Federal Legislative Developments , accessed February 2, 2026, Semaglutide shortage gives rise to unauthorized products, accessed February 2, 2026, GLP-1 Solution September 09, 2025 FDA, accessed February 2, 2026, GLP-1 Weight Loss Drug Enforcement in 2025: State Attorneys General Step into a Growing Regulatory Gap Stevens & Lee, accessed February 2, 2026, Non-Traditional Channels: The Compounded GLP-1 Market IQVIA, accessed February 2, 2026, With compounders out of the way, Lilly and Novo go after each other PharmaVoice, accessed February 2, 2026, The Great Convergence: Pharmaceuticals, Digital Health, and the Direct-to-Patient Paradigm DrugPatentWatch Transform Data into Market Domination, accessed February 2, 2026, A Strategic Guide to White Space Analysis for Pharmaceutical R&D DrugPatentWatch Transform Data into Market Domination, accessed February 2, 2026, Eli Lilly, Novo Nordisk report strong earnings as GLP-1 race heats up, accessed February 2, 2026, Patent and Innovation Trends in GLP-1 and Weight Loss Drugs (20202025): What the IP and Science Signal Next | Cypris, accessed February 2, 2026, Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices
